Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Specific investigations: other studies

Currently viewing:

Administrative data

specific investigations: other studies
Type of information:
experimental study
Adequacy of study:
disregarded due to major methodological deficiencies
3 (not reliable)
Rationale for reliability incl. deficiencies:
significant methodological deficiencies
static inhalation exposure with unclear exposure; extremely high exposure; partially no dose relationship; Chinese publication with English summary

Data source

Reference Type:
Toxic effect of MMA to the reproductive system of male mice
Wang C., Chen X, Cao S.
Bibliographic source:
Zhiye Yu Jiankang (2011), 27(9), 970-972

Materials and methods

Principles of method if other than guideline:
To study the toxic effect of methylmethacrylate (MMA) to reproductive system of the male mammals.Through sperm shape abnormality test of the rats mice and the examinations of the testicular and seminal vesicle's viscera coefficient in the male mice, the experimental data were analyzed by the methods of χ2 test and variance analysis.
GLP compliance:
not specified
Type of method:
in vivo
Endpoint addressed:
toxicity to reproduction / fertility

Test material

Constituent 1
Chemical structure
Reference substance name:
Methyl methacrylate
EC Number:
EC Name:
Methyl methacrylate
Cas Number:
Molecular formula:
methyl 2-methylprop-2-enoate
Test material form:

Test animals

other: Kunming

Administration / exposure

Route of administration:
inhalation: vapour
not specified
Details on exposure:
static inhalative exposure in a 50 L chamber
Analytical verification of doses or concentrations:
not specified
Duration of treatment / exposure:
2 h
Frequency of treatment:
daily on 5 consecutive days
Post exposure period:
30 days since the 1st treatment
Doses / concentrationsopen allclose all
Dose / conc.:
6.55 mg/L air
corresponds to 50% of the LC50
Dose / conc.:
13.1 mg/L air
corresponds to 100% of the LC50
Dose / conc.:
26.2 mg/L air
corresponds to 200% of the LC50
No. of animals per sex per dose:
Control animals:


Positive control:
cyclophosphamide 30 mg/kg administered by intraperitoneal injection

Results and discussion

Details on results:
Clinical signs: Severe clinical signs were observed; Low dose = 50% LC50: commotion, fleeing, jumping, grasping at the walls; Mid dose = 100% LC50: decreased movement, hobbling gait or even lateral lying, occasional tumultuous jumping; high dose = 200% LC50: Appearance of fluffy and unclean dorsal hairs, significantly reduced activity, aggregation lateral laying with reduced breathing

Sperm deformity rates were 1.80%, 2.46 and 2.58%, respectively, for the treatment groups and 1.42% in the for negative control group and 3.72% in the positive control group. Medium and high dose groups: the rate of sperm deformity in mice was significantly higher than that in the negative control group, with a uniform difference of (P<0.01); while the sperm deformity rate in mice in the low-dose group compared with the negative control group, the difference was not statistically significant (P>0.05).
Sperm deformities due to MMA are predominantly head deformities.

Testicular organ weight coefficients were comparable to the negative control.
Seminal vesicle gland organ weight coefficient of the high dose group was significantly different to the negative control group (P<0.05).

Applicant's summary and conclusion